NEKTAR GETS $17.6 MILLION FROM AFFYMAX PACT FOR HEMATIDE.
Nektar Therapeutics (Nasdaq:NKTR), San Carlos. Calif., has received
a $17.6 million payment under a previously undisclosed license agreement
with Affymax, Inc. The cash payment under the . . .
LIPONEX PROVIDES CLINICAL TRIAL UPDATE.
Liponex Inc. (TSX:LPX), Ottawa, Canada, a biopharmaceutical company
specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," . . .
SPHERIX SIGNS ANACLIM TO SUPPORT DIABETES CLINICAL TRIAL.
Spherix Incorporated (NASDAQ:SPEX), Beltsville, Md., has signed an
agreement with Anaclim, LLC to conduct the U.S. portion of its Phase 3
clinical trial on the use of Naturlose(R) as a treatment . . .
XCELERON GETS AWARD FOR INTERNATIONAL ACHIEVEMENT.
Xceleron, U.K., a pioneering service provider specializing in
zeptoanalysis to accelerate drug development, has won the Yorkshire
Bioscience Award for International Achievement. The award, . . .
BIOPARTNERS REMAINS POSITIVE AFTER ALPHENON CHMP RULING.
BioPartners, Baar, Switzerland, a privately-owned
biopharmaceuticals company has expressed disappointment that its
biosimilar Interferon Alpha, Alpheon(R), had received a negative opinion
from the . . .
MEDIVIR OUTLICENSES TWO NEW ANTIVIRAL PROJECTS TO
TIBOTEC.
Medivir AB (STO:MVIRB), Stockholm, Sweden, has signed two new
pharmaceutical license agreements and an extension of the ongoing
research collaboration in hepatitis C (HCV) with Tibotec . . .
OREXO PRESENTS POSITIVE STUDY RESULTS FOR SUBLINOX.
Orexo has presented a positive study result for Sublinox (OX 22) at
APSS (Associated Professional Sleep Societies) in Salt Lake City, USA.
The results from the Sublinox (OX 22) study demonstrates . . .
FDA APPROVES TEVA'S ANDA TO MARKET GENERIC VERSION OF
ZOCOR.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), Jerusalem,
Israel, has announced that the U.S. Food and Drug Administration has
granted final approval for the company's Abbreviated New . . .
BIOCRYST/GREEN CROSS TO DEVELOP PERAMIVIR IN SOUTH KOREA.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Birmingham, Ala., has
signed an agreement with Green Cross Corporation, South Korea for the
development and commercialization in Korea of peramivir, . . .
ONCOLYTICS ISSUED U.S. PATENT FOR PRODUCING REOVIRUS.
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), Calgary, has been
granted U.S. Patent 7,049,127 entitled "Method of Producing
Infectious Reovirus." The claims describe a method for producing
and . . .
MD BIOSCIENCES LAUNCHES NEUROLOGY DISCOVERY SERVICES.
MD Biosciences, Herzelia-Pituah, Israel, a global biotechnology
company focused in inflammations research, has expanded its Israel
facility with the launch of its Neurology Discovery Services. . . .
LABOPHARM GRANTS TRAMDOL MARKETING RIGHTS TO PURDUE
PHARMA.
Labopharm Inc.(TSX: DDS) and Purdue Pharma L.P. sign a definitive
licensing and distribution agreement under which Labopharm, through its
subsidiary, Labopharm Europe Limited, has granted Purdue . . .
UCB SELLS OTC DELSYM TO ADAMS RESPIRATORY THERAPEUTICS.
UCB S.A., Brussels, Belgium, has reached an agreement with Adams
Respiratory Therapeutics Inc. (NASDAQ: ARxT) to sell Delsym
(dextromethorphan polistirex), an over-the-counter (OTC) 12-hour . . .
UCB COMPLETES MUTUAL RECOGNITION PROCEDURE FOR EQUASYM
XL.
UCB, Brussels, Belgium, has successfully completed the European
Mutual Recognition Procedure (MRP) for Equasym(TM) XL for use in the
treatment of the symptoms of attention deficit hyperactivity . . .
BERLEX JOINS STRATEGIC DIAGNOSTICS IN ANTIBODY EFFORT.
Strategic Diagnostics Inc. (Nasdaq:SDIX), Newark, Del. a leading
provider of biotechnology-based detection solutions for a broad range of
food, water, agricultural, industrial, environmental and . . .
BREAST RECONSTRUCTION STUDY INITIATED IN JAPAN.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (Frankfurt:XMPA) has
received approval to begin an investigator-initiated safety and
feasibility study in Japan using adult adipose (fat) derived stem . . .
NIH FUNDS CLINICAL DEVELOPMENT OF VIVAGEL FOR GENITAL
HERPES.
Starpharma Holdings Limited (USOTC: SPHRY; ASX: SPL), Melbourne,
Australia, has signed an agreement with the National Institute of
Allergy and Infectious Diseases (NIAID), part of the National . . .
CRUCELL/US NAVY SIGN PACT TO TEST ADVAC-BASED VACCINE.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL),
Leiden, The Netherlands, has signed a Cooperative Research and
Development Agreement (CRADA) with the Naval Medical Research . . .
BIOVITRIM/SANTHERA SIGN PACT FOR DEVELOPING DPP-IV.
Biovitrum and Santhera have signed an exclusive license and
collaboration agreement for the development of DPP-IV inhibitors for the
treatment of type 2 diabetes and other metabolic diseases
. . .
INCLONE/UCB TO DEVELOP/COMMERCIALIZE CDP-791.
ImClone Systems Incorporated (NASDAQ: IMCL) and UCB have entered
into a worldwide strategic partnership for the development and
commercialization of CDP-791, a novel, investigational . . .
|
|